AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).

Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).

ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial investigating the use of zerlasiran (SLN360), a double-stranded small interfering ribonucleic acid (siRNA), in adults with elevated lipoprotein(a) at high risk of ASCVD events. 180 patients were enrolled in the trial and were followed-up at 36, 48 and 60 weeks. The primary outcome measure was time averaged change in lipoprotein(a) from baseline.

Interview Questions:
1.    What is the importance behind the ALPACAR trial?
2.    Could you tell us about the mechanism of action behind zerlasiran?
3.    What were the key findings?
4.    What further research is needed in this area, and what are the next steps?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.